|Bid||0.00 x 1800|
|Ask||0.00 x 1200|
|Day's Range||8.95 - 10.11|
|52 Week Range||7.01 - 30.99|
|Beta (5Y Monthly)||-1.97|
|PE Ratio (TTM)||5.54|
|Earnings Date||Aug 11, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
The roller-coaster-like trajectory that has been Co-Diagnostics' (NASDAQ: CODX) stock price climbed another hill on Thursday. Co-Diagnostics announced that its CoPrimer diagnostics platform, which underpins testing products -- like its popular-for-obvious-reasons Logix Smart for COVID-19 -- has been granted a patent in South Korea. "We believe that this patent granted by South Korea provides additional validation of the uniqueness and versatility of the CoPrimer platform," the company quoted CEO Dwight Egan as saying.
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea's Intellectual Property Office for the Company's CoPrimer™ technology.
In this article we will analyze whether Co-Diagnostics, Inc. (NASDAQ:CODX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into […]